| [1] |
He J, Zhang R, Shao M , et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: A randomised, double-blind, placebo-controlled trial[J/OL]. Ann Rheum Dis, 2019, 9(2019-09-19)[2019-10-01]. .
|
| [2] |
He J, Zhang X, Wei Y , et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus[J]. Nat Med, 2016,22(9):991-993.
|
| [3] |
Rosenzwajg M, Lorenzon R, Cacoub P , et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial[J]. Ann Rheum Dis, 2019,78(2):209-217.
|
| [4] |
Morgan DA, Ruscetti FW, Gallo R . Selective in vitro growth of T lymphocytes from normal human bone marrows[J]. Science, 1976,193(4257):1007-1008.
|
| [5] |
Mizel SB, Farrar JJ . Revised nomenclature for antigen-nonspecific T-cell proliferation and helper factors[J]. Cell Immunol, 1979,48(2):433-436.
|
| [6] |
Shao Q, Gao H,. Progress in interleukin-2 therapy for rheumatic immune diseases by regulating the immune balance of T cells[J/OL]. Scand J Immunol, 2019, 9(2019-09-08)[2019-10-01].
|
| [7] |
Sakaguchi S, Wing K, Miyara M . Regulatory T cells: A brief history and perspective[J]. Eur J Immunol, 2007,37(Suppl 1):116-123.
|
| [8] |
Harrington LE, Hatton RD, Mangan PR , et al. Interleukin 17-producing CD4+effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages [J]. Nat Immunol, 2005,6(11):1123-1132.
|
| [9] |
Zhao Z, Zhang X, Su L , et al. Fine tuning subsets of CD4+T cells by low-dosage of IL-2 and a new therapeutic strategy for autoimmune diseases [J]. Int Immunopharmacol, 2018,56:269-276.
|
| [10] |
Kim HS, Jang SW, Lee W , et al. PTEN drives Th17 cell differentiation by preventing IL-2 production[J]. J Exp Med, 2017,214(11):3381-3398.
|
| [11] |
Osnes LT, Nakken B, Bodolay E , et al. Assessment of intracellular cytokines and regulatory cells in patients with autoimmune diseases and pri-mary immunodeficiencies: Novel tool for diagnostics and patient follow-up[J]. Autoimmun Rev, 2013,12(10):967-971.
|
| [12] |
Li J, Lu E, Yi T , et al. EBI2 augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells[J]. Nature, 2016,533(7601):110-114.
|
| [13] |
Shao M, He J, Zhang R , et al. Interleukin-2 deficiency associated with renal impairment in systemic lupus erythematosus[J]. J Interferon Cytokine Res, 2019,39(2):117-124.
|
| [14] |
Shin MS, Lee N, Kang I . Effector T-cell subsets in systemic lupus erythematosus: Update focusing on Th17 cells[J]. Curr Opin Rheumatol, 2011,23(5):444-448.
|
| [15] |
Betts BC, Pidala J, Kim J , et al. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation[J]. Haematologica, 2017,102(5):948-957.
|
| [16] |
Zhao XY, Zhao XS, Wang YT , et al. Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study[J]. Oncoimmunology, 2016,5(12):e1250992.
|
| [17] |
Saadoun D, Rosenzwajg M, Joly F , et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis[J]. N Engl J Med, 2011,365(22):2067-2077.
|
| [18] |
Hartemann A, Bensimon G, Payan CA , et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2013,1(4):295-305.
|
| [19] |
Zhang J, Ruan Y, Shen Y , et al. Low dose IL-2 increase regulatory T cells and elevate platelets in a patient with immune thrombocytopenia[J]. Cytometry B Clin Cytom, 2018,94(3):400-404.
|
| [20] |
Zhang J, Ruan Y, Xu X , et al. Therapeutic potential of low-dose IL-2 in immune thrombocytopenia: An analysis of 3 cases[J]. Cytom B Clin Cytom, 2018,94(3):428-433.
|
| [21] |
Castela E, Le Duff F, Butori C , et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata[J]. JAMA Dermatol, 2014,150(7):748-751.
|
| [22] |
Miao M, Hao Z, Guo Y , et al. Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with pri-mary Sjögren’s syndrome[J]. Ann Rheum Dis, 2018,77(12):1838-1840.
|
| [23] |
Zhang S, Wang J, Sun H , et al. Circulating regulatory T cells were absolutely decreased in dermatomyositis/polymyositis patients and restored by low-dose IL-2[J/OL]. Ann Rheum Dis, 2019, 10(2019-10-14)[2019-10-16].
|
| [24] |
An H, Li X, Li F , et al. The absolute counts of peripheral T lymphocyte subsets in patient with ankylosing spondylitis and the effect of low-dose interleukin-2[J]. Medicine (Baltimore), 2019,98(15):e15094.
|
